ArticleAmyotrophic lateral sclerosis & frontotemporal degeneration2013
Myelin imaging in amyotrophic and primary lateral sclerosis.
Article in Amyotrophic lateral sclerosis & frontotemporal degeneration, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Microstructure-Informed Myelin Mapping (MIMM) from routine multi-echo gradient echo data using multiscale physics modeling of iron and myelin effects and QSM.Magnetic resonance in medicine · 2025Article
- The Role of Glial Cell Senescence in Alzheimer's Disease.Journal of neurochemistry · 2025Review
- Primary lateral sclerosis associated with PSEN1 Pro284Leu variant in a Colombian family: Clinical and neuropathological features.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Harnessing myelin water fraction as an imaging biomarker of human cerebral aging, neurodegenerative diseases, and risk factors influencing myelination: A review.Journal of neurochemistry · 2024Review
- Myelin Pathology in Alzheimer's Disease: Potential Therapeutic Opportunities.Aging and disease · 2024Review
- Primary Lateral Sclerosis: An Overview.Journal of clinical medicine · 2024Review
- Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage.Frontiers in molecular neuroscience · 2024Review
- Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms.Molecular neurodegeneration · 2023Review
- Aberrant Ganglioside Functions to Underpin Dysregulated Myelination, Insulin Signalling, and Cytokine Expression: Is There a Link and a Room for Therapy?Biomolecules · 2022Review
- High-resolution quantitative MRI of multiple sclerosis spinal cord lesions.Magnetic resonance in medicine · 2022Article
- Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis.Human brain mapping · 2022Article
- Defective Oligodendroglial Lineage and Demyelination in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2021Review
- Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging.Frontiers in neurology · 2021Review
- Focal alterations of the callosal area III in primary lateral sclerosis: An MRI planimetry and texture analysis.NeuroImage. Clinical · 2020Article
- Article
- Longitudinal associations between white matter maturation and cognitive development across early childhood.Human brain mapping · 2019Article
- Hereditary primary lateral sclerosis and progressive nonfluent aphasia.Journal of neurology · 2019Article
- Prospective study of myelin water fraction changes after mild traumatic brain injury in collegiate contact sports.Journal of neurosurgery · 2019Article
- Rapid myelin water imaging for the assessment of cervical spinal cord myelin damage.NeuroImage. Clinical · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Primary lateral sclerosis (PLS) has been regarded as a rare, extreme form of amyotrophic lateral sclerosis (ALS). Like ALS, it is a clinical diagnosis without established biomarkers. We sought to explore loss of cerebral myelin in relation to clinical features, including cognitive impairment, in cases of both ALS and PLS. A novel MRI sequence (mcDESPOT) sensitive to water pools within myelin and intra- and extra-cellular spaces was applied to 23 ALS patients, seven PLS patients and 12 healthy controls, with interval follow-up in 15 ALS and four PLS patients. Results demonstrated that PLS patients were distinguished by widespread cerebral myelin water fraction reductions, independent of disease duration and clinical upper motor neuron burden. ALS patients showed a significant increase in intra- and extra-cellular water, indirectly linked to neuroinflammatory activity. Limited measures of cognitive impairment in the ALS group were associated with myelin changes within the anterior corpus callosum and frontal lobe projections. Longitudinal changes were only significant in the PLS group. In conclusion, in this exploratory study, myelin imaging has potential to distinguish PLS from ALS, and may have value as a marker of extramotor involvement. PLS may be a more active cerebral pathological process than its rate of clinical deterioration suggests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.